Galecto Inc. (GLTO) NASDAQ
$1.29 0.07 (5.74%)
Market Cap: $32.59M
As of 05/25/22 04:00 PM EDT. Market closed.
Galecto Inc. (GLTO) NASDAQ
$1.29 0.07 (5.74%)
Market Cap: $32.59M
As of 05/25/22 04:00 PM EDT. Market closed.
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. The Company's team has ... read more
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. The Company's team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. read less
Open in:
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Lindmark Bertil | Chief Medical Officer | Mar 22, 2022 | Buy | $2.16 | 14,604 | 31,545 | 16,604 | Mar 23, 2022, 08:00 AM |
| Schambye Hans T. | Chief Executive Officer | Mar 22, 2022 | Buy | $2.15 | 5,000 | 10,750 | 52,428 | Mar 23, 2022, 08:00 AM |
| Winslow Garrett | General Counsel | Dec 03, 2021 | Buy | $2.48 | 2,000 | 4,960 | 4,000 | Dec 06, 2021, 08:00 AM |
| Freve Jonathan | Chief Financial Officer | Dec 03, 2021 | Buy | $2.49 | 4,000 | 9,960 | 12,000 | Dec 06, 2021, 08:00 AM |
| Schambye Hans T. | Chief Executive Officer | Nov 09, 2021 | Buy | $3.50 | 4,500 | 15,750 | 47,428 | Nov 10, 2021, 08:00 AM |
| Freve Jonathan | Chief Financial Officer | Nov 08, 2021 | Buy | $3.40 | 3,000 | 10,200 | 8,000 | Nov 09, 2021, 08:00 AM |
| Freve Jonathan | Chief Financial Officer | Aug 18, 2021 | Buy | $3.92 | 3,000 | 11,760 | 5,000 | Aug 19, 2021, 04:00 PM |
| Lindmark Bertil | Chief Medical Officer | Jun 28, 2021 | Buy | $5.26 | 2,000 | 10,520 | 2,000 | Jun 28, 2021, 04:00 PM |
| Schambye Hans T. | Chief Executive Officer | Jun 24, 2021 | Buy | $5.11 | 3,000 | 15,330 | 42,928 | Jun 24, 2021, 04:00 PM |
| Freve Jonathan | Chief Financial Officer | Jun 23, 2021 | Buy | $4.74 | 2,000 | 9,480 | 2,000 | Jun 23, 2021, 04:00 PM |
| Winslow Garrett | General Counsel | Jun 23, 2021 | Buy | $4.80 | 2,000 | 9,600 | 2,000 | Jun 23, 2021, 04:00 PM |
| ORBIMED ADVISORS LLC | Director | Nov 02, 2020 | Buy | $15.00 | 733,333 | 10,999,995 | 2,579,657 | Nov 04, 2020, 08:00 PM |
| Khuong Chau Quang | Director | Nov 02, 2020 | Buy | $15.00 | 733,333 | 10,999,995 | 2,579,657 | Nov 04, 2020, 08:00 PM |
| Christgau Stephan | Director | Nov 02, 2020 | Buy | $15.00 | 66,666 | 999,990 | 546,136 | Nov 04, 2020, 08:00 PM |
| Novo Holdings A/S | 10% Owner | Nov 02, 2020 | Buy | $15.00 | 333,333 | 4,999,995 | 2,497,791 | Nov 04, 2020, 07:52 PM |
| Owner | Relationship | Date | Value($) |
| Lindmark Bertil | Chief Medical Officer | 03/22/2022 | 31,545 |
| Schambye Hans T. | Chief Executive Officer | 03/22/2022 | 10,750 |
| Winslow Garrett | General Counsel | 12/03/2021 | 4,960 |
| Freve Jonathan | Chief Financial Officer | 12/03/2021 | 9,960 |
| Schambye Hans T. | Chief Executive Officer | 11/09/2021 | 15,750 |
| Freve Jonathan | Chief Financial Officer | 11/08/2021 | 10,200 |
| Freve Jonathan | Chief Financial Officer | 08/18/2021 | 11,760 |
| Lindmark Bertil | Chief Medical Officer | 06/28/2021 | 10,520 |
| Schambye Hans T. | Chief Executive Officer | 06/24/2021 | 15,330 |
| Freve Jonathan | Chief Financial Officer | 06/23/2021 | 9,480 |
| Winslow Garrett | General Counsel | 06/23/2021 | 9,600 |
| ORBIMED ADVISORS LLC | Director | 11/02/2020 | 10,999,995 |
| Khuong Chau Quang | Director | 11/02/2020 | 10,999,995 |
| Christgau Stephan | Director | 11/02/2020 | 999,990 |
| Novo Holdings A/S | 10% Owner | 11/02/2020 | 4,999,995 |
Period of Report: 03/31/2022
10-K/10-Q Filings: View